A new antibody treatment reduced levels of type I interferon-producing cells in patients with cutaneous lupus, improving skin symptoms during phase 1 clinical trials.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.
